Serum laminin γ2 monomer as a predictive biomarker for hepatocellular carcinoma in patients with chronic hepatitis B virus infection: a retrospective cohort study.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
25 Oct 2024
25 Oct 2024
Historique:
received:
25
12
2023
accepted:
18
10
2024
medline:
26
10
2024
pubmed:
26
10
2024
entrez:
25
10
2024
Statut:
epublish
Résumé
This retrospective study evaluated the use of laminin γ2 monomer (LG2m) as a predictive biomarker for hepatocellular carcinoma (HCC) in patients with chronic hepatitis B virus (HBV) infection. Serum LG2m levels were measured in two cohorts of patients: cohort 1 comprised 56 patients with chronic liver disease for assessing LG2m stability, whereas cohort 2 included 89 patients with chronic HBV infection who did not have HCC for evaluating the usefulness of LG2m measurement in HCC prediction. LG2m was highly stable in cryopreserved serum, and an increased LG2m level was significantly associated with a higher risk of HCC in chronically HBV-infected patients (P = 0.012). Multivariable Cox regression analysis revealed that high LG2m was an independent significant risk factor for HCC (hazard ratio, 7.16; 95% confidence interval, 1.31-39.2; P = 0.023). These findings suggest that LG2m may serve as a useful biomarker for the prediction of future HCC in patients with chronic HBV infection.
Identifiants
pubmed: 39455696
doi: 10.1038/s41598-024-77068-4
pii: 10.1038/s41598-024-77068-4
doi:
Substances chimiques
Laminin
0
Biomarkers, Tumor
0
LAMC2 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
25395Subventions
Organisme : Japan Agency for Medical Research and Development
ID : JP23ck0106662h
Organisme : Japan Agency for Medical Research and Development
ID : JP23ck0106662h
Organisme : Japan Agency for Medical Research and Development
ID : JP23ck0106662h
Organisme : Japan Agency for Medical Research and Development
ID : JP23ck0106662h
Organisme : Japan Agency for Medical Research and Development
ID : JP23ck0106662h
Organisme : Japan Agency for Medical Research and Development
ID : JP23ck0106662h
Organisme : Japan Agency for Medical Research and Development
ID : JP23fk0210122
Organisme : Japan Society for the Promotion of Science
ID : JP21H02900
Informations de copyright
© 2024. The Author(s).
Références
Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71(3), 209–249 (2021).
doi: 10.3322/caac.21660
pubmed: 33538338
Fattovich, G., Stroffolini, T., Zagni, I. & Donato, F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology. 127(5 Suppl 1), S35-50 (2004).
doi: 10.1053/j.gastro.2004.09.014
pubmed: 15508101
Yamashita, T. et al. Serum laminin gamma2 monomer as a diagnostic and predictive biomarker for hepatocellular carcinoma. Hepatology 74(2), 760–775 (2021).
doi: 10.1002/hep.31758
pubmed: 33609304
Koshikawa, N. et al. Overexpression of laminin gamma 2 chain monomer in invading gastric carcinoma cells. Cancer Res. 59(21), 5596–5601 (1999).
pubmed: 10554040
Yasuda, H. et al. Unique biological activity and potential role of monomeric laminin-γ2 as a novel biomarker for hepatocellular carcinoma: A review. Int. J. Mol. Sci. 20(1), 226 (2019).
doi: 10.3390/ijms20010226
pubmed: 30626121
pmcid: 6337480
Hlubek, F., Jung, A., Kotzor, N., Kirchner, T. & Brabletz, T. Expression of the invasion factor laminin gamma2 in colorectal carcinomas is regulated by beta-catenin. Cancer Res. 61(22), 8089–8093 (2001).
pubmed: 11719433
Giannelli, G., Fransvea, E., Bergamini, C., Marinosci, F. & Antonaci, S. Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin. Cancer Res. 9(10 Pt 1), 3684–3691 (2003).
pubmed: 14506159